1. Taiwan Stocks

  2. •

    Technology services

  3. •

    Packaged software
Acer Medical Inc.

Acer Medical Inc.

TTPEX:6857
90.50
TWD
-0.50
(-0.55%)
1.43BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.19
1.24
1.06
1.8
3.29
3.94
- -
Basic EPS, GAAP
-1.08
-2.29
-2.64
-4.43
-2.51
-1.8
-1.95
- -
Free Cash Flow per Basic Share
-0.54
-0.69
-2.54
-4.31
-3.54
-1.36
-1.69
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.3
2.35
9.21
17.08
14.58
12.78
10.83
10.23
Tangible Book Value per Share
3.3
2.35
9.18
16.8
14.28
12.53
10.62
9.89
Basic Weighted Avg Shares
5
5
8
12
15
15
15
15
Sales/Revenue/Turnover
- -
1
10
13
27
50
60
- -
Operating Margin (%)
-6,752.94
-1,185.21
-213.28
-422.49
-149.96
-60.2
-54.51
- -
Depreciation Expense
- -
- -
- -
1
1
1
1
- -
Net Income, GAAP
-6
-12
-20
-55
-38
-27
-30
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-6,622.35
-1,176.04
-212.38
-418.88
-139.1
-54.56
-49.43
- -
Working Capital
41
29
114
253
212
189
158
146
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
41
29
115
260
222
195
165
156
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-33.88
-28.39
-29.18
-15.84
-13.14
-16.51
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
3
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
1,827
1,507
1,430

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
203
200
181
Cash, Cash Equivalents & STI
182
179
154
Accounts Receivable, Net
11
11
15
Inventories
4
6
5
Total Current Liabilities
30
42
35
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
- -
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
75.4%
-15.25%
Free Cash Flow
- -
116.01%
24.29%
Net Income, GAAP
- -
37.79%
8.49%
Sales/Revenue/Turnover
- -
219.54%
19.73%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
50
2025
- -
- -
60
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.8
2025
- -
- -
-1.95
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia En Lien
Full Time Employees
22
Sector
Technology services
Industry
Packaged software
Address
No. 88, Section 1, Xintai 5th Road New Taipei TP Taiwan
IPO Date
Oct 27, 2021
Website
acer-medical.com
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
Acer Medical Inc. (6857.TWO) develops and provides artificial intelligence-based medical diagnostic software and telemedicine solutions for the healthcare sector. Founded in 2018 and headquartered in New Taipei City, Taiwan, the company, a subsidiary of Acer Group, offers AI-assisted screening products including VeriSee DR for diabetic retinopathy identification; VeriSee AMD for age-related macular degeneration screening; VeriOsteo OP for bone mineral density abnormality detection using chest X-rays; ARC-1000; aiMed, a generative AI service platform launched in September 2025 that converts healthcare professionals' voice or text into structured medical records; and VeriCompact. It also provides telemedicine services such as telepresence clinics for chronic condition consultations in homes and facilities; and telecare sites for specialist consultations at health clinics, targeting medical facilities, practitioners, and patients in domestic Taiwan and overseas markets including Southeast Asia, Indonesia, and Malaysia. Recent developments include VeriOsteo OP obtaining medical device approval from Indonesia's Ministry of Health in October 2025; deepened partnership with Yongxin Pharmaceuticals to promote VeriOsteo OP and VeriSee DR through clinics, pharmacies, and labs in 2024; launch of aiMed for Taiwan market rollout in October 2025 with plans for Southeast Asia and Europe; and collaboration with Intel incorporating OpenVINO technology on Intel Core Ultra processors for optimized VeriSee deployment in Malaysian hospitals like Universiti Malaysia Sabah Hospital as of March 2025; alongside showcasing VeriSee solutions at the Malaysian Ophthalmology Society Annual Congress.